Physician profile
Wei G Lin
NPI 1043381569
$8,238.45
in general payments reported to CMS, 2019-2025
18 companies · $879 in 2025
The $879 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,854 · 2020: $694 · 2021: $1,317 · 2022: $1,047 · 2023: $1,476 · 2024: $971 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,312 · Education: $14.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,311.87 |
| Education | $14.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,848.52 | 2019-2025 | Repatha, Otezla, Otezla |
| Gilead Sciences, INC. | $1,535.93 | 2019-2025 | Vemlidy |
| Amarin Pharma, INC. | $606.91 | 2019-2022 | |
| Abbvie INC. | $569.64 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $559.46 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $181.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.01 | 2022-2024 | |
| Novo Nordisk INC | $124.76 | 2025 | Wegovy |
| Intuitive Surgical, INC. | $123.45 | 2024 | |
| Horizon Therapeutics Plc | $120.48 | 2023 | Tepezza |
| Merck Sharp & Dohme LLC | $115.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.00 | 2019 | |
| Insmed, INC. | $81.24 | 2019-2021 | |
| Seqirus USA INC | $31.71 | 2024-2025 | Flucelvax |
| Vivus LLC | $24.75 | 2025 | Pancreaze |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.15 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $14.63 | 2025 | Rexulti |
| Allergan, INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.